• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
MHFTR

Testimonial

Diary, Newsletter

I've been reading your blog for a while and found it a helpful beacon in a sea of confusing and contradictory information as I try and make sense of the world (and try and make money from sense!).

Kind regards,
Toby
London, England

 

https://www.madhedgefundtrader.com/wp-content/uploads/2018/05/John-with-wine-glass-story-3-image-e1526508431419.jpg 273 250 MHFTR https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png MHFTR2020-02-12 04:02:352020-02-11 17:33:43Testimonial
MHFTR

February 12, 2020 - Quote of the Day

Diary, Newsletter, Quote of the Day

"The Obamacare website had technical issues all week because of too much web traffic. You can't campaign on the fact that too many people don't have health care, and then be surprised that millions don't have health care. That's like 1-800-FLOWERS being caught off guard by Valentine's Day," said a comedian on Saturday Night Live.

https://www.madhedgefundtrader.com/wp-content/uploads/2018/05/Dead-flowers-quote-of-the-day-e1526507959892.jpg 266 200 MHFTR https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png MHFTR2020-02-12 04:00:182020-02-11 17:35:15February 12, 2020 - Quote of the Day
Mad Hedge Fund Trader

Quote of the Day - February 13, 2020

Diary, Newsletter, Quote of the Day

“The bubble is in the bond market, not the stock market,” said Leon Cooperman, CEO of Omega Advisors, an original investor in my 1990s hedge fund.

https://www.madhedgefundtrader.com/wp-content/uploads/2020/01/leon-copperman.png 272 410 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-02-12 04:00:082020-02-12 19:36:37Quote of the Day - February 13, 2020
Douglas Davenport

February 11, 2020 - MDT Alert (KEX)

MDT Alert

With the market literally sitting up against the extreme upper band on the daily chart, I am real quick to pull the trigger on a deal if it is not making a strong push.

And because of that, I am going to suggest you close the KEX position.

Sell to Close (2) March 20th - $75.00 calls @ $3.10
The 2 calls will cost $5.20

Sell to Close (1) March 20th - $75.00 put @ 2.70

The total credit will be $8.80 per position.

Closing the position will result in a small profit of about $120.00.

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Douglas Davenport https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Douglas Davenport2020-02-11 14:22:492020-02-11 14:23:07February 11, 2020 - MDT Alert (KEX)
Mad Hedge Fund Trader

February 11, 2020 - MDT Pro Tips A.M.

MDT Alert

While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-02-11 09:13:252020-02-11 09:13:25February 11, 2020 - MDT Pro Tips A.M.
Mad Hedge Fund Trader

February 11, 2020

Biotech Letter

Mad Hedge Biotech & Healthcare Letter
February 11, 2020
Fiat Lux

Featured Trade:

(NOVO NORDISK IS MINING GOLD WITH DIABETES)
(NVO), (LLY)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-02-11 08:02:302020-02-11 07:27:18February 11, 2020
Mad Hedge Fund Trader

Novo Nordisk is Mining Gold With Diabetes

Biotech Letter

Diabetes is one of the fastest-growing and serious health conditions that affect the lives of over 50% of Americans, with 60 million more categorized as pre-diabetics. As expected, the market for diabetes treatments is saturated.

However, this biotechnology company has been hailed as one of the leaders in this sector: Novo Nordisk (NVO).

Novo Nordisk has long established itself as a major player in this lucrative market, with diabetes treatments in its portfolio primarily responsible for the 24% jump of the stock’s performance in 2019 -- an increase that has been sustained up until today.

The company’s lineup includes a number of insulin products such as Tresiba and NovoRapid, with Novo Nordisk supplying roughly 50% of the insulin distributed globally.

Meanwhile, its top-selling Type 2 diabetes drug Ozempic ranked first among all the drugs launched in 2018.

 Capitalizing on the success of Ozempic as a blockbuster insulin injectable, Novo Nordisk has gained FDA approval to market this bestselling drug as a treatment to reduce the risk of major adverse cardiovascular (CV) condition among patients of Type 2 diabetes.

This is actually an impressive move since diabetics are more often than not also suffering from other comorbidities like kidney problems, obesity, and CV disease.

With this expanded indication involving CV risk reduction, Novo Nordisk’s cash cow will be on par with heavyweights like Bristol-Myers Squibb (BMY) and AstraZeneca’s (AZN) Farxiga as well as Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly’s (LLY) Jardiance.

Ozempic, which was first approved way back in December 2017 as a diabetes medication and launched in the market by 2018, has long been considered the company’s strongest moneymaker.

In fact, the first nine months of 2019 saw Ozempic bring in roughly $1 billion in sales worldwide.

Still riding the momentum of its diabetes treatments, Novo Nordisk also recently received another label upgrade that classifies its recently approved oral tablet Rybelsus as CV safe as well. Projected sales for this drug now lands somewhere between $2 billion and $5 billion.

In addition to CV diseases, Novo Nordisk has also enjoyed success on other fronts like obesity.

For instance, the company’s prescription weight loss shot Saxenda has been gaining sales momentum since its release in 2014.

The fact that Saxenda can also help improve blood sugar levels for pre-diabetic patients has made it the first of its kind across the globe.

Earning $540 million in 2018, which represented a 50% jump from its 2017 sales, Saxenda is estimated to own a 68% share of the obesity market.

Saxenda’s dominance was once again proven in its third-quarter earnings report in 2019 when the drug gained an impressive 56% increase compared to the same period in the previous year.

Novo Nordisk shares come with a bit of a steep price though, and investors are hesitant over the strong reliance of the company on its diabetes lineup. After all, 84% of its sales in the third quarter of 2019 came from this line of business alone.

However, the recent approval and expanded indication of Rybelsus as another groundbreaking Type 2 diabetes treatment both in the US and abroad makes Novo Nordisk a highly coveted investment.

Keep in mind that over 90% of diabetes cases fall under that type, so the company is poised to dominate not only a lucrative sector but also an addressable target market.

Apart from that, the early and mid-stage pipeline of Novo Nordisk offers a promising lineup.

The company has been consistent with its strategy, and that is focusing on its strengths then building on them. Right now, Novo Nordisk has a lot of up and coming candidates not only for its tried and tested diabetes market but for rare diseases as well. 

Thus, Novo Nordisk sales are expected to continue its upward trajectory in 2020. If this trend continues, the company can double its earnings practically every five years.

 

https://www.madhedgefundtrader.com/wp-content/uploads/2020/02/nvo.png 254 335 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-02-11 08:00:052020-02-11 07:27:47Novo Nordisk is Mining Gold With Diabetes
Mad Hedge Fund Trader

February 11, 2020

Diary, Newsletter

Global Market Comments
February 10, 2020
Fiat Lux

Featured Trade:

(THE MAD HEDGE FUND TRADER’S FAVORITE ONLINE BROKER)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-02-11 04:04:492020-02-10 18:26:54February 11, 2020
Mad Hedge Fund Trader

February 10, 2020 - MDT Alert (IRBT)

MDT Alert

Today, I would like to make a suggestion on a stock that I believe should continue to get a bounce and follow through to the upside.

The stock is iRobot Corp (IRBT).

I would like to use the same structure as the trade we just put on with KEX.

That is the unequal straddle.

IRBT reported on February 7th, so there is no scheduled earnings event in the near future.

IRBT is trading around $52.54 as I write this.

The suggestion will be an unequal straddle with a bullish bias.
 
The idea will be to buy 2 calls for every 1 put.

Buy to Open (2) February 28th - $52.50 calls @ $2.40. The 2 calls will cost $4.80

Buy to Open (1) February 28th - $52.50 put @ $2.50

The total debit will be $7.30 per position.

Based on the nominal portfolio, limit the trade to a 2 lot or a total of $1,460.  This is a 1.5% risk based on the nominal portfolio.

The end result if you trade the suggested position size is that you will own (4) February 28th - $52.50 calls and (2) February 28th - $52.50 puts.

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-02-10 14:19:592020-02-10 14:19:59February 10, 2020 - MDT Alert (IRBT)
Mad Hedge Fund Trader

February 10, 2020

Tech Letter

Mad Hedge Technology Letter
February 10, 2020
Fiat Lux

Featured Trade:

(THE MODERN AGE TECH FORCE MULTIPLIER)
(GOOGL)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-02-10 09:04:432020-02-10 08:14:58February 10, 2020
Page 170 of 187«‹168169170171172›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Scroll to top